These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 39195205

  • 1. Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria.
    Lewis RE, Palombo M, Diani E, Secci B, Gibellini D, Gaibani P.
    Cells; 2024 Aug 06; 13(16):. PubMed ID: 39195205
    [No Abstract] [Full Text] [Related]

  • 2. In Vitro Activity of New β-Lactam-β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019.
    Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, Yang Y, Wu S, Yin D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Microbiol Spectr; 2022 Aug 31; 10(4):e0185422. PubMed ID: 35862963
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.
    Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C, ARTEMIS Study Investigators.
    Microbiol Spectr; 2024 Apr 02; 12(4):e0383623. PubMed ID: 38483164
    [Abstract] [Full Text] [Related]

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 02; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP.
    Eur J Clin Microbiol Infect Dis; 2024 Sep 02; 43(9):1787-1794. PubMed ID: 38995343
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
    Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M.
    J Glob Antimicrob Resist; 2024 Sep 02; 38():12-20. PubMed ID: 38789082
    [Abstract] [Full Text] [Related]

  • 7. Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant Acinetobacter spp.
    Wong O, Mezcord V, Lopez C, Traglia GM, Pasteran F, Tuttobene MR, Corso A, Tolmasky ME, Bonomo RA, Ramirez MS.
    Microbiol Spectr; 2024 Oct 03; 12(10):e0093024. PubMed ID: 39162493
    [Abstract] [Full Text] [Related]

  • 8. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):380-386. PubMed ID: 30357343
    [Abstract] [Full Text] [Related]

  • 9. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy.
    Bassetti M, Monti G, Henriksen AS, Longshaw C.
    Antimicrob Resist Infect Control; 2024 Aug 26; 13(1):91. PubMed ID: 39183351
    [Abstract] [Full Text] [Related]

  • 10. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul 26; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 11. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C, Freire S, Nordmann P, Poirel L.
    Eur J Clin Microbiol Infect Dis; 2024 Feb 26; 43(2):339-354. PubMed ID: 38095831
    [Abstract] [Full Text] [Related]

  • 12. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I, Zer Y, Bosnak VK, Mete AO, Namiduru M.
    J Int Med Res; 2013 Dec 26; 41(6):1830-7. PubMed ID: 24265334
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
    Weber C, Schultze T, Göttig S, Kessel J, Schröder A, Tietgen M, Besier S, Burbach T, Häussler S, Wichelhaus TA, Hack D, Kempf VAJ, Hogardt M.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0169722. PubMed ID: 36190424
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Shields RK, Clancy CJ, Pasculle AW, Press EG, Haidar G, Hao B, Chen L, Kreiswirth BN, Nguyen MH.
    J Clin Microbiol; 2018 Feb 26; 56(2):. PubMed ID: 29167294
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.